Wenghoefer Matthias, Pesch Beate, Harth Volker, Broede Peter, Fronhoffs Stefan, Landt Olfert, Brüning Thomas, Abel Josef, Bolt Hermann M, Herberhold Claus, Vetter Hans, Ko Yon-Dschun
Department of Oncology (Medizinische Universitäts-Poliklinik), University of Bonn, Wilhelmstrasse 35-37, 53111 Bonn, Germany.
Arch Toxicol. 2003 Jan;77(1):37-41. doi: 10.1007/s00204-002-0414-y. Epub 2002 Oct 26.
Tobacco-associated carcinogens are catalyzed by microsomal epoxide hydrolase (mEH). Combinations of the Y113H and H139R polymorphic EPHX1 variants have been assumed to alter the enzyme activity and thus the risk of squamous cell head and neck cancer (SCCHN). Based on in vitro data, a putative low, medium and high mEH activity has been associated with combinations of these genotypes, and the respective activity categories have been frequently used in the estimation of risks for smoking-related cancers. We investigated the SCCHN risk for EPHX1 genotypes among 280 cases and 289 controls. We could not detect main effects of the EPHX1 genotypes, but a smaller risk of the 139HR genotype in smokers (odds ratio, OR, 0.57; 95% confidence interval, CI, 0.34-0.95). We could not confirm an increase of the SCCHN risk for genotype combinations according to a putative medium and high enzyme activity (OR 1.28, 95% CI 0.84-1.96; OR 0.98, 95% CI 0.58-1.64, respectively), but a significant heterogeneity of the estimated risks for the singular genotypes within these categories among smokers ( P=0.02). Further, p53 mutations among smoking cases were less frequent in the group with a putative high enzyme activity, although insignificant due to small numbers (OR 0.54, 95% CI 0.13-2.17). This supports uncertainties in categorizing genotypes with respect to limited enzyme activity data, especially when taken from in vitro experiments.
烟草相关致癌物由微粒体环氧化物水解酶(mEH)催化。Y113H和H139R多态性EPHX1变体的组合被认为会改变酶活性,从而影响鳞状细胞头颈癌(SCCHN)的风险。基于体外数据,假定低、中和高mEH活性与这些基因型的组合相关,并且在估计吸烟相关癌症风险时经常使用相应的活性类别。我们调查了280例病例和289例对照中EPHX1基因型的SCCHN风险。我们未检测到EPHX1基因型的主要影响,但吸烟者中139HR基因型的风险较小(优势比,OR,0.57;95%置信区间,CI,0.34 - 0.95)。我们无法证实根据假定的中高酶活性,基因型组合会增加SCCHN风险(OR分别为1.28,95%CI 0.84 - 1.96;OR 0.98,95%CI 0.58 - 1.64),但吸烟者中这些类别内单个基因型估计风险存在显著异质性(P = 0.02)。此外,假定高酶活性组中吸烟病例的p53突变频率较低,尽管由于数量少无统计学意义(OR 0.54,95%CI 0.13 - 2.17)。这支持了在根据有限的酶活性数据对基因型进行分类时存在的不确定性,特别是从体外实验获取的数据。